Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

The proteome response to amyloid protein expression in vivo.

Gomes RA, Franco C, Da Costa G, Planchon S, Renaut J, Ribeiro RM, Pinto F, Silva MS, Coelho AV, Freire AP, Cordeiro C.

PLoS One. 2012;7(11):e50123. doi: 10.1371/journal.pone.0050123. Epub 2012 Nov 21.

2.

Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.

McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colón W.

Biochemistry. 1995 Oct 17;34(41):13527-36.

PMID:
7577941
4.
5.
6.

Polyglutamine-rich suppressors of huntingtin toxicity act upstream of Hsp70 and Sti1 in spatial quality control of amyloid-like proteins.

Wolfe KJ, Ren HY, Trepte P, Cyr DM.

PLoS One. 2014 May 14;9(5):e95914. doi: 10.1371/journal.pone.0095914. eCollection 2014.

7.

Comparative proteome analysis of Saccharomyces cerevisiae: a global overview of in vivo targets of the yeast activator protein 1.

Jun H, Kieselbach T, Jönsson LJ.

BMC Genomics. 2012 Jun 9;13:230. doi: 10.1186/1471-2164-13-230.

9.

Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.

Ferrão-Gonzales AD, Palmieri L, Valory M, Silva JL, Lashuel H, Kelly JW, Foguel D.

J Mol Biol. 2003 May 9;328(4):963-74.

PMID:
12729768
10.

Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis.

Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Oshima T, Mori Y, Mizuguchi M, Ueda M, Shono M, Obayashi K, Arima H, Ando Y.

Biochem J. 2011 Jul 1;437(1):35-42. doi: 10.1042/BJ20110041.

PMID:
21668413
11.

Ribosome-tethered molecular chaperones: the first line of defense against protein misfolding?

Craig EA, Eisenman HC, Hundley HA.

Curr Opin Microbiol. 2003 Apr;6(2):157-62. Review.

PMID:
12732306
12.
13.
14.

The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.

Morais-de-Sá E, Neto-Silva RM, Pereira PJ, Saraiva MJ, Damas AM.

Acta Crystallogr D Biol Crystallogr. 2006 May;62(Pt 5):512-9. Epub 2006 Apr 19.

PMID:
16627944
15.

Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.

Shnyrov VL, Villar E, Zhadan GG, Sanchez-Ruiz JM, Quintas A, Saraiva MJ, Brito RM.

Biophys Chem. 2000 Dec 15;88(1-3):61-7.

PMID:
11152276
16.

Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.

Sörgjerd K, Ghafouri B, Jonsson BH, Kelly JW, Blond SY, Hammarström P.

J Mol Biol. 2006 Feb 17;356(2):469-82. Epub 2005 Dec 5.

PMID:
16376939
17.

Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell.

Sato T, Susuki S, Suico MA, Miyata M, Ando Y, Mizuguchi M, Takeuchi M, Dobashi M, Shuto T, Kai H.

EMBO J. 2007 May 16;26(10):2501-12. Epub 2007 Apr 12.

18.

Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells.

Kamata M, Susanto MT, Chen IS.

J Gene Med. 2009 Feb;11(2):103-11. doi: 10.1002/jgm.1276.

PMID:
19065606
19.

Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.

Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM.

J Biol Chem. 2001 Jul 20;276(29):27207-13. Epub 2001 Apr 16.

20.

Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.

Palhano FL, Leme LP, Busnardo RG, Foguel D.

J Biol Chem. 2009 Jan 16;284(3):1443-53. doi: 10.1074/jbc.M807100200. Epub 2008 Nov 4.

Supplemental Content

Support Center